Citizens Financial Group Inc. RI Buys 25,954 Shares of Pfizer Inc. $PFE

Citizens Financial Group Inc. RI boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 9.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 309,137 shares of the biopharmaceutical company’s stock after acquiring an additional 25,954 shares during the period. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $7,444,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Handelsbanken Fonder AB grew its stake in shares of Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after acquiring an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Pfizer by 15.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after purchasing an additional 745,213 shares during the period. Vanguard Group Inc. grew its position in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. Leuthold Group LLC purchased a new stake in Pfizer during the 2nd quarter valued at $4,887,000. Finally, North Dakota State Investment Board purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $5,348,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PFE shares. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and cut their price target for the company from $32.00 to $28.00 in a report on Monday, July 6th. Guggenheim cut their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a report on Tuesday, June 9th. Finally, UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Stock Up 0.8%

PFE opened at $28.00 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market cap of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The business’s fifty day moving average is $25.30 and its two-hundred day moving average is $26.25.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the company posted $0.78 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer’s dividend payout ratio is presently 226.32%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.